Table 4:
Cancer-specific mortality associations related to transplanted organ or cancer-specific biological features.
| Cancer Deaths | Cancer-specific mortality rate | HR | 95%CI | aHR1* | 95%CI | ||
|---|---|---|---|---|---|---|---|
| Analyses for selected cancers, by transplanted organ | |||||||
| Kidney cancer | |||||||
| Kidney recipient | 230 | 52.4 | 0.65 | (0.57, 0.74) | 1.23 | (1.08, 1.40) | |
| Non-kidney recipient | 54 | 64.3 | 0.74 | (0.57, 0.97) | 1.21 | (0.93, 1.58) | |
| Non-recipient | 71,838 | 68.4 | 1 | 1 | |||
| Lung cancer | |||||||
| Lung recipient | 107 | 421.8 | 0.86 | (0.71, 1.04) | 1.45 | (1.20, 1.75) | |
| Non-lung recipient | 1,248 | 550.5 | 1.11 | (1.05, 1.17) | 1.35 | (1.27, 1.42) | |
| Non-recipient | 870,934 | 424.9 | 1 | 1 | |||
| Liver cancer | |||||||
| Liver recipient | 42 | 298.0 | 0.61 | (0.45, 0.82) | 0.59 | (0.44, 0.80) | |
| Non-liver recipient | 76 | 475.1 | 0.85 | (0.68, 1.06) | 1.02 | (0.81, 1.27) | |
| Non-recipient | 63,953 | 606.1 | 1 | 1 | |||
| Analyses for selected cancers, by biological features of the cancer | |||||||
| Breast cancer† | |||||||
| ER positive cases | |||||||
| Recipient | 41 | 41.7 | 1.95 | (1.43, 2.64) | 2.94 | (2.16, 4.00) | |
| Non-recipient | 28,141 | 21.6 | 1 | referent | 1 | referent | |
| ER negative cases | |||||||
| Recipient | 31 | 105.3 | 1.77 | (1.25, 2.52) | 2.21 | (1.56, 3.15) | |
| Non-recipient | 17,735 | 56.6 | 1 | 1 | referent | ||
| Colorectal cancer | |||||||
| Colon cancer | |||||||
| Recipient | 301 | 147.6 | 1.48 | (1.32, 1.66) | 1.81 | (1.62, 2.03) | |
| Non-recipient | 259,781 | 76.2 | 1 | referent | 1 | referent | |
| Rectal cancer | |||||||
| Recipient | 68 | 91.0 | 1.05 | (0.82, 1.33) | 1.59 | (1.26, 2.02) | |
| Non-recipient | 112,786 | 77.2 | 1 | referent | 1 | referent | |
| Lung cancer‡ | |||||||
| Adenocarcinoma | |||||||
| Recipient | 468 | 564.5 | 1.28 | (1.17, 1.40) | 1.56 | (1.42, 1.70) | |
| Non-recipient | 283,598 | 346.1 | 1 | referent | 1 | referent | |
| Squamous cell | |||||||
| Recipient | 399 | 363.6 | 0.87 | (0.79, 0.96) | 1.09 | (0.98, 1.20) | |
| Non-recipient | 190,938 | 383.7 | 1 | referent | 1 | referent | |
| Other NSCLC | |||||||
| Recipient | 329 | 752.6 | 1.17 | (1.05, 1.30) | 1.47 | (1.32, 1.64) | |
| Non-recipient | 238,823 | 561.1 | 1 | referent | 1 | referent | |
| SCLC | |||||||
| Recipient | 154 | 1445.6 | 1.63 | (1.39, 1.91) | 1.67 | (1.42, 1.95) | |
| Non-recipient | 152,187 | 719.3 | 1 | referent | 1 | referent | |
Abbreviations: HR,hazard ratio;aHR,adjusted hazard ratio;CI,confidence interval;ER,estrogen receptor;NSCLC,non-small cell lung cancer;SCLC,small cell lung cancer
Cox models were adjusted for age (<40,40–84 in 5 year increments,85+), sex, race (white,black,other), stage (local,regional,distant,unknown), and diagnosis year (1987–1991,1992–1996,1997–2001,2002–2005,2006–2009, 2010–2014).
Cases were restricted to diagnosis dates 2004–2014. ER status was missing for breast cancers in 15.3% of transplant recipients and 16.6% of non-recipients.
Adenocarcinoma was identified with histology codes: {8140,8141,8143–8145,8147,8190, 8250,8255,8260, 8262,8263,8290,8320,8323,8480,8481,8570–8574,8576}; squamous cell was identified with histology codes: 8052,8070–8076,8078; other NSCLC was identified with histology codes: {8010–8015,8020–8022,8030–8035,8040,8046,8050,8051,8082:8084,8146,8210,8230,8231,8244,8246,8251–8254,8280,8310, 8313,8315, 8330,8333,8341,8345,8350,8500,8510,8512,8520,8521,8525,8530,8550,8551,8560,8562,8575,9015}; SCLC was defined with histology codes: 8041–8045.